Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Culmerciclib Combination Regimen in HR+/HER2- Breast Cancer Insensitive to Neoadjuvant TAC
NCT07900516Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of culmerciclib in breast cancer, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Objective Response Rate at 18 weeks. Started Aug 2026; status: recruiting.
02
Drugs
culmerciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07900516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07900516.